These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1363 related items for PubMed ID: 29181556

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients.
    Bock F, Frerker B, Schubert L, Rennau H, Kurth J, Krause BJ, Hildebrandt G, Schwarzenböck SM.
    Nuklearmedizin; 2024 Jun; 63(3):199-206. PubMed ID: 38580313
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.
    BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.
    Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, Vogel-Claussen J, Christiansen H, Derlin T.
    Strahlenther Onkol; 2016 Jul; 192(7):431-9. PubMed ID: 27272755
    [Abstract] [Full Text] [Related]

  • 49. Utility of 68 Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.
    Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS.
    J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
    Staal FHE, Janssen J, Brouwer CL, Langendijk JA, Ng Wei Siang K, Schuit E, de Jong IJ, Verzijlbergen JF, Smeenk RJ, Aluwini S.
    BMC Cancer; 2022 Apr 15; 22(1):416. PubMed ID: 35428210
    [Abstract] [Full Text] [Related]

  • 53. Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease.
    Furman B, Falick Michaeli T, Den R, Ben Haim S, Popovtzer A, Wygoda M, Blumenfeld P.
    Cancer Imaging; 2024 Jul 29; 24(1):96. PubMed ID: 39075567
    [Abstract] [Full Text] [Related]

  • 54. 68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
    Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE.
    Prostate; 2017 Jun 29; 77(8):920-927. PubMed ID: 28317152
    [Abstract] [Full Text] [Related]

  • 55. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May 29; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 56. Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy.
    Onal C, Torun N, Oymak E, Guler OC, Reyhan M, Yapar AF.
    Ann Nucl Med; 2020 Jun 29; 34(6):388-396. PubMed ID: 32221791
    [Abstract] [Full Text] [Related]

  • 57. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
    Francolini G, Detti B, Bottero M, Zilli T, Lancia A, Bruni A, Borghesi S, Mariotti M, Castellucci P, Fanti S, Filippi AR, Teriaca MA, Maragna V, Aristei C, Mazzeo E, Livi L, Ingrosso G.
    Clin Transl Oncol; 2021 Feb 29; 23(2):364-371. PubMed ID: 32602076
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 69.